Emerson Electric Co. vs Pfizer Inc — how do they compare? Emerson Electric Co. trades at $159.06 (market cap $88.72B), while Pfizer Inc trades at $27.79 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Pfizer Inc for 158 Days on average.
| EMR | PFE | |
|---|---|---|
Market Cap | $88.72B | $158.56B |
Volume | 2,355,255 | 44,138,282 |
Sector | Industrials | Health |
52-Week High | $164.38 | $29.02 |
52-Week Low | $123.30 | $23.67 |
Typical Hold Time | 81 Days | 158 Days |
Enterprise Value | $99.80B | $210.06B |
Dividend Yield | 1.4% | 6.18% |
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% on the day, near its pivot point of $159. The stock shows a bullish technical trend with moving averages supporting upside momentum. Fundamentally, EMR delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected to reach $18.6B in 2026, while profitability remains solid with a net income margin of 13.83% in 2025.
The outlook for EMR is positive, supported by analyst consensus favoring a Buy rating (53.49%) and a $165.90 price target implying ~4% upside. Key risks include volatile cash flows, with net cash flow negative in 2025, and elevated debt levels. Investor sentiment is bolstered by strong institutional coverage and recent dividend declarations, though macroeconomic pressures on industrials warrant caution.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →